Plain-English translation of NCT03683680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers at Dana-Farber Cancer Institute are working to develop a better way to determine the stage and prognosis of malignant pleural mesothelioma. Right now, doctors cannot accurately predict how advanced the cancer is before surgery or treatment begins. This study collects small tissue samples during your routine diagnostic biopsy to test whether new laboratory tests can more accurately classify your cancer stage and give a better prediction of your outlook.
Currently, doctors don't have a reliable way to determine mesothelioma stage before treatment starts, which makes it hard to predict how the disease will progress. This study aims to validate a new method that could give patients and doctors better information to guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you qualify, the study team will collect tissue samples during your already-scheduled diagnostic biopsy or chest procedure — no additional surgery or visits are needed. The researchers will store and study these samples to test whether the new staging method works accurately. Your participation involves allowing the research team to use tissue from your routine care, and the study team will follow your medical progress over time.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States
Sponsor
Dana-Farber Cancer Institute
Collaborators
National Cancer Institute (NCI)
Enrollment target
~240 participants
Started
October 2018
Primary completion
January 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Raphael Bueno, MD
Brigham and Women's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.